6:02 AM ET
8-K
Clinical Trial Data
Kyverna Therapeutics Clinical Trial Data
Kyverna Therapeutics announced positive one-year topline data from its KYSA-8 registrational trial for miv-cel in stiff person syndrome (SPS) and longer-term follow-up data from its KYSA-6 trial in generalized myasthenia gravis (gMG). The results demonstrated durable clinical responses and a favorable safety profile, supporting the company's plan to complete a rolling BLA submission for SPS in Q4 2026.
- Earnings call
- Sep 29, 2026, 10:15 AM ET